F., Lingvay, I., McGowan, B
It feels like a relief
Phase 2 dose-escalation data showed mean weight loss of 24.2% at 48 weeks at the highest dose tested substantially exceeding semaglutide's 14.9% and approaching tirzepatide's 22.5% in comparable timeframes
Withhold XIGDUO XR, if possible, in temporary clinical situations that could predispose patients to ketoacidosis
TRIUMPH-1 enrolled approximately 2,300 patients and is expected to complete around mid-year
The combined benefits of reduced appetite, increased satiety, slower gastric emptying, and improved blood sugar control make GLP-1 therapy an effective weight loss solution, particularly for individuals who have found it challenging to lose weight with diet and exercise alone